Hematology · 2007 · 19 citations · 28 references
MedicineHematologyCell TherapyStem Cell TransplantationTransplant ImmunologyAllogeneic Stem Cell TransplantationConditioning RegimensEngraftment MonitoringHematologic Malignancy TherapyHematopoietic Stem Cell TransplantationReduced-intensity ConditioningAcute Myeloid Leukemia TreatmentClinical RemissionPost-transplant Relapse ProphylaxisRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRefractory LeukemiaRelapsed Acute Myeloid LeukemiaSecond Remission
Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective strategy for preventing relapse of acute myelogenous leukemia (AML). We analyzed the outcome of 31 primary AML patients who received a reduced-intensity conditioning regimen for allogeneic HSCT in first or second remission. Thirty-one AML patients, 20 in first complete remission (FCR), 8 in second complete remission (SCR) and 3 in a partial remission (SPR) were included. All received busulfan 4 mg/kg/d/2 days, fludarabine 30 mg/m(2)/d/3 days and cyclophosphamide 350 mg/m(2)/d/3 days as conditioning regimen. The median number of CD34+ cells infused was 5.6 x 10(6)/kg and 5.2 x 10(6) in FCR and SCR group, respectively. All patients received cyclosporine-A (CsA) and methotrexate as graft vs. host disease (GvHD) prophylaxis. All patients showed myeloid engraftment (neutrophils >0.5 x 10(9)/l) after a median of 13 days in FCR group and 15 days in SCR group. Platelet recovery >20 x 10(9)/l was achieved after a median of 13 days in both groups. Relapse for 20 patients in FCR was 35% compared to 91% for 11 in SCR/SPR (p < 0.05). Conclusions. Reduced-intensity conditioning followed by allogeneic HSCT can induce stable remission in primary AML patients transplanted in FCR. A high relapse rate was documented in patients with refractory or relapsed AML.
28
The Medical Journal of Australia · 1999 · 3.4K citations
Chronic graft-versus-host syndrome in man
Howard M. Shulman, Keith M. Sullivan, Paul L. Weiden et al. · The American Journal of Medicine · 1980 · 2.4K citations
Life Sciences, Immunology, Surgery +10
HJ Kolb, A Schattenberg, JM Goldman et al. · Blood · 1995 · 2K citations · Full text
Medicine, Hematology, Immunology +16
Shimon Slavin, Arnon Nagler, E Naparstek et al. · Blood · 1998 · 1.9K citations · Full text
Medicine, Hematology, Oncology +17